Lisa Flower, MD
Family Medicine · Fairmont, WVNPI 1659394922
Payments from drug & device makers
Across 701 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- AstraZeneca$1K
- Amgen$1K
- Lilly USA, LLC$944
- Pfizer$803
- plus $4K from 30 others
What the payments were for
- Food & beverage$11,24799%
- Education$1671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $1,787 |
| Novo Nordisk | 79 | $1,301 |
| AstraZeneca | 63 | $1,075 |
| Amgen(2 entities) | 64 | $1,046 |
| Lilly USA, LLC | 60 | $944 |
| Pfizer | 47 | $803 |
| Astellas Pharma US Inc | 41 | $678 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $634 |
| Boehringer Ingelheim | 39 | $576 |
| Exact Sciences | 20 | $338 |
| Bayer | 20 | $326 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $248 |
| Sanofi-aventis U.S. LLC | 15 | $211 |
| Johnson & Johnson | 11 | $167 |
| Merck | 11 | $146 |
| GSK | 10 | $146 |
| Abbott | 7 | $144 |
| Kowa Pharmaceuticals America, Inc. | 11 | $143 |
| E.r. Squibb & Sons, L.L.C. | 10 | $137 |
| Eisai Inc. | 6 | $114 |
| Phathom Pharmaceuticals, Inc. | 4 | $67 |
| Amarin Pharma, Inc. | 4 | $57 |
| Medtronic | 2 | $50 |
| Biohaven Pharmaceuticals, Inc. | 2 | $36 |
| Novartis | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Organon | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Mayne Pharma Commercial LLC | 1 | $18 |
| Philips North America LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
How this compares
$11,414 in reported general payments places this provider in the 95th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 147 | $183,842 |
| OzempicSemaglutide | 85 | $107,179 |
| JanuviaSitagliptin Phosphate | 53 | $65,916 |
| MounjaroTirzepatide | 44 | $50,251 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $35,374 |
| TradjentaLinagliptin | 37 | $28,629 |
| EliquisApixaban | 41 | $28,437 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $24,599 |
| InvokanaCanagliflozin | 17 | $14,082 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $12,571 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $11,022 |
| BelsomraSuvorexant | 23 | $10,525 |
| Bupropion XlBupropion Hcl | 73 | $7,217 |
| VeozahFezolinetant | 11 | $5,508 |
| Novolog FlexpenInsulin Aspart | 16 | $4,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $576 | $225,042204 claims |
| Novo NordiskOzempic | $1,301 | $107,17985 claims |
| MerckJanuvia, Belsomra | $146 | $76,44176 claims |
| Lilly USA, LLCMounjaro | $944 | $50,25144 claims |
| PfizerEliquis | $803 | $28,43741 claims |
| GSKTrelegy Ellipta | $146 | $24,59927 claims |
| Johnson & JohnsonInvokana | $167 | $14,08217 claims |
| Astellas Pharma US IncVeozah | $678 | $5,50811 claims |
| AbbVieSynthroid | $1,787 | $2,34838 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Fairmont
- Marilyn BonfiliFairmont$12K
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Julie DetempleSouth Charleston$129K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
- Courtney PilkertonMorgantown$45K
- Isha WoofterClarksburg$27K
- Dominick WoofterClarksburg$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.